title: Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls.
authors.affiliation: Drs. Daughton and Kratochvil are with the University of Nebraska Medical Center. Electronic address: jdaughto@unmc.edu.
authors.forename: Joan M
authors.initials: JM
authors.lastname: Daughton
authors.affiliation: Drs. Daughton and Kratochvil are with the University of Nebraska Medical Center.
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Kratochvil
mesh_terms: D000293:Adolescent; D000316:Adrenergic alpha-Agonists / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D016642:Bupropion / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D002648:Child; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes; D016527:Drug Costs / Q000706:statistics & numerical data; D006801:Humans; D011437:Propylamines / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000316:Adrenergic alpha-Agonists; D000697:Central Nervous System Stimulants; D003692:Delayed-Action Preparations; D011437:Propylamines; D016642:Bupropion; D000069445:Atomoxetine Hydrochloride